WO2009024686A3 - Procede de production de formes pharmaceutiques seches hydrodispersibles - Google Patents

Procede de production de formes pharmaceutiques seches hydrodispersibles Download PDF

Info

Publication number
WO2009024686A3
WO2009024686A3 PCT/FR2008/000973 FR2008000973W WO2009024686A3 WO 2009024686 A3 WO2009024686 A3 WO 2009024686A3 FR 2008000973 W FR2008000973 W FR 2008000973W WO 2009024686 A3 WO2009024686 A3 WO 2009024686A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrodispersible
novel method
pharmaceutical forms
pharmaceutically
pharmaceutical compositions
Prior art date
Application number
PCT/FR2008/000973
Other languages
English (en)
Other versions
WO2009024686A2 (fr
Inventor
Patrice Binay
Original Assignee
Coretecholding
Patrice Binay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coretecholding, Patrice Binay filed Critical Coretecholding
Priority to RU2010103999/15A priority Critical patent/RU2497502C2/ru
Priority to BRPI0814027-8A2A priority patent/BRPI0814027A2/pt
Priority to JP2010514045A priority patent/JP5560188B2/ja
Priority to EP08827662A priority patent/EP2192894A2/fr
Priority to US12/452,543 priority patent/US20130064897A1/en
Priority to CA2694059A priority patent/CA2694059A1/fr
Publication of WO2009024686A2 publication Critical patent/WO2009024686A2/fr
Publication of WO2009024686A3 publication Critical patent/WO2009024686A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L' invention se rapporte au domaine des nécessités de la vie et plus particulièrement à celui de la santé. Elle a plus particulièrement pour objet un procédé pour mettre en solution et améliorer la résorption intestinale de principes actifs peu solubles dans l'eau ou insolubles dans l'eau ou non salifiables dans le suc gastrique d'un ou plusieurs principe (s) actif (s) dispersés dans un ester d'acide gras de polyoxyéthylène 32 puis à pulvériser à chaud cette dispersion sur un excipient granulaire en lit fluidisé. Le mélange pulvérulent ainsi formé est distribué dans des compositions pharmaceutiques après dilution éventuelle par un excipient inerte non toxique pharmaceutiquement acceptable. Application à la réalisation de compositions pharmaceutiques renfermant un ou plusieurs excipients inertes non toxiques, pharmaceutiquement acceptables.
PCT/FR2008/000973 2007-07-06 2008-07-07 Procede de production de formes pharmaceutiques seches hydrodispersibles WO2009024686A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
RU2010103999/15A RU2497502C2 (ru) 2007-07-06 2008-07-07 Новый способ получения сухих фармацевтических форм, диспергируемых в воде, и фармацевтические композиции, полученные таким способом
BRPI0814027-8A2A BRPI0814027A2 (pt) 2007-07-06 2008-07-07 Processo de produção de formas farmacêuticas secas hidrodispersíveis
JP2010514045A JP5560188B2 (ja) 2007-07-06 2008-07-07 水分散性の乾いた形態の医薬品の新規製造方法およびそれに伴い得られる医薬組成物
EP08827662A EP2192894A2 (fr) 2007-07-06 2008-07-07 Procede de production de formes pharmaceutiques seches hydrodispersibles
US12/452,543 US20130064897A1 (en) 2007-07-06 2008-07-07 New process for producing hydrodispexible dry pharmaceutical composition and the pharmaceutical compositions thus obtained
CA2694059A CA2694059A1 (fr) 2007-07-06 2008-07-07 Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions pharmaceutiques ainsi obtenues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704874A FR2918277B1 (fr) 2007-07-06 2007-07-06 Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
FR0704874 2007-07-06

Publications (2)

Publication Number Publication Date
WO2009024686A2 WO2009024686A2 (fr) 2009-02-26
WO2009024686A3 true WO2009024686A3 (fr) 2009-04-23

Family

ID=39469562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000973 WO2009024686A2 (fr) 2007-07-06 2008-07-07 Procede de production de formes pharmaceutiques seches hydrodispersibles

Country Status (9)

Country Link
US (1) US20130064897A1 (fr)
EP (1) EP2192894A2 (fr)
JP (1) JP5560188B2 (fr)
KR (1) KR20100038188A (fr)
BR (1) BRPI0814027A2 (fr)
CA (1) CA2694059A1 (fr)
FR (1) FR2918277B1 (fr)
RU (1) RU2497502C2 (fr)
WO (1) WO2009024686A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006679A1 (fr) * 1990-10-16 1992-04-30 Kabi Pharmacia Ab Procede de formulation medicamenteuse et composition pharmaceutique
WO2001045677A1 (fr) * 1999-12-20 2001-06-28 Kerkhof Nicholas J Procede de production de particules d'echelle nanometrique par sechage par atomisation en lit fluidise
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2004028505A1 (fr) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques sous forme solide contenant du telmisartan
WO2005051358A1 (fr) * 2003-11-19 2005-06-09 Alza Corporation Composition et procede pour l'amelioration de la biodisponibilite
US20050163855A1 (en) * 2004-01-27 2005-07-28 Cj Corporation Method of preparing low-crystallinity oltipraz or amorphous oltipraz

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
EP1680091B1 (fr) 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S Forme de dose solide comprenant un fibrate
US7635745B2 (en) * 2006-01-31 2009-12-22 Eastman Chemical Company Sulfopolyester recovery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006679A1 (fr) * 1990-10-16 1992-04-30 Kabi Pharmacia Ab Procede de formulation medicamenteuse et composition pharmaceutique
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001045677A1 (fr) * 1999-12-20 2001-06-28 Kerkhof Nicholas J Procede de production de particules d'echelle nanometrique par sechage par atomisation en lit fluidise
WO2004028505A1 (fr) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques sous forme solide contenant du telmisartan
WO2005051358A1 (fr) * 2003-11-19 2005-06-09 Alza Corporation Composition et procede pour l'amelioration de la biodisponibilite
US20050163855A1 (en) * 2004-01-27 2005-07-28 Cj Corporation Method of preparing low-crystallinity oltipraz or amorphous oltipraz

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. SEO ET AL.: "Effects of droplet size and type of binder on the agglomerate growth mechanism by melt agglomeration in a fluidised bed.", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 16, 2002, pages 95 - 105, XP002483385 *

Also Published As

Publication number Publication date
US20130064897A1 (en) 2013-03-14
JP5560188B2 (ja) 2014-07-23
BRPI0814027A2 (pt) 2015-02-03
FR2918277A1 (fr) 2009-01-09
EP2192894A2 (fr) 2010-06-09
CA2694059A1 (fr) 2009-02-26
JP2010532336A (ja) 2010-10-07
FR2918277B1 (fr) 2012-10-05
WO2009024686A2 (fr) 2009-02-26
RU2010103999A (ru) 2011-08-20
RU2497502C2 (ru) 2013-11-10
KR20100038188A (ko) 2010-04-13

Similar Documents

Publication Publication Date Title
WO2009024686A3 (fr) Procede de production de formes pharmaceutiques seches hydrodispersibles
ES2527390T3 (es) Composición basada en fexofenadina y procedimiento de preparación para la misma
ES2453477T3 (es) Composición de excipiente coprocesada para un comprimido, su preparación y uso
CN1530139A (zh) 包含三氯蔗糖的组合物
CA2969860A1 (fr) Compositions et procedes pour ameliorer une performance athletique
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
TWI812602B (zh) 含二胺衍生物之口腔崩散錠及其製造方法
US10555909B2 (en) Microencapsulation of B-alanine
WO2008032767A1 (fr) Comprimé se désintegrant oralement et procédé de fabrication de celui-ci
TWI556823B (zh) 含阿卡波糖之口崩解錠
BRPI0501091A (pt) comprimido de domperidona rapidamente dispersìvel em água
RU2017143849A (ru) Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения
JP2006514100A5 (fr)
CN102327244B (zh) 一种盐酸氨溴索口腔崩解片及其制备方法
CA2796541A1 (fr) Pastilles d'erythritol et d'isomalt
WO2009084041A3 (fr) Compositions pharmaceutiques de dexibuprofène
CN102599494A (zh) 一种含维生素c的三层泡腾片的制备工艺
JP5476782B2 (ja) アルギニン含有錠剤の製造方法
WO2017060920A1 (fr) Compositions pharmaceutiques
CN103082295A (zh) 一种含b族维生素的三层泡腾片的制备工艺
JP5902677B2 (ja) エリトリトール及びイソマルトの口腔内崩壊性錠剤
JP2008517909A (ja) 圧縮性の悪い活性物質及びトコフェロールポリエチレングリコールスクシネート（ｔｐｇｓ）を含む錠剤
CN1762354B (zh) 一种含有钙阻滞剂的稳定药物组合物
JP6004702B2 (ja) 不快味が軽減された固形製剤の製造方法
JP6407085B2 (ja) 錠剤およびその製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827662

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010514045

Country of ref document: JP

Ref document number: 2008827662

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107000196

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12452543

Country of ref document: US

Ref document number: 2694059

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010103999

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0814027

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100104